Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Trotabresib by Bristol-Myers Squibb for Solid Tumor: Likelihood of Approval
Trotabresib is under clinical development by Bristol-Myers Squibb and currently in Phase I for Solid Tumor. According to GlobalData, Phase...
Risk adjusted net present value: What is the current valuation of Bristol-Myers Squibb's Trotabresib?
Trotabresib is a small molecule commercialized by Bristol-Myers Squibb, with a leading Phase I program in Solid Tumor. According to...
Risk adjusted net present value: What is the current valuation of Bristol-Myers Squibb's Trotabresib?
Trotabresib is a small molecule commercialized by Bristol-Myers Squibb, with a leading Phase II program in Glioblastoma Multiforme (GBM). According...